Targeting acetylcholinesterase and butyrylcholinesterase in dementia.
The cholinesterase inhibitors (ChE-Is) attenuate the cholinergic deficit underlying the cognitive and neuropsychiatric dysfunctions in patients with AD. Inhibition of brain acetylcholinesterase (AChE) has been the major therapeutic target of ChE-I treatment strategies for Alzheimer's disease (AD). AChE-positive neurons project diffusely to the cortex, modulating cortical processing and responses to new and relevant stimuli. Butyrylcholinesterase (BuChE)-positive neurons project specifically to the frontal cortex, and may have roles in attention, executive function, emotional memory and behaviour. Furthermore, BuChE activity progressively increases as the severity of dementia advances, while AChE activity declines. Therefore, inhibition of BuChE may provide additional benefits. The two cholinesterase (ChE) enzymes that metabolize acetylcholine (ACh) differ significantly in substrate specificity, enzyme kinetics, expression and activity in different brain regions, and complexity of gene regulation. In addition, recent evidence suggests that AChE and BuChE may have roles beyond 'classical' co-regulatory esterase functions in terminating ACh-mediated neurotransmission. 'Non-classical' roles in modulating the activity of other proteins, regional cerebral blood flow, tau phosphorylation, and the amyloid cascade may affect rates of AD progression. If these additional mechanisms are demonstrated to underlie clinically meaningful effects, modification of the over-simplistic cholinergic hypothesis in AD that is limited to symptomatic treatment, ignoring the potential of cholinergic therapies to modify the disease process, may be appropriate. The specificity of ChE inhibitory activity, up-regulation of AChE activity and changes in the composition of AChE molecular forms over time, selectivity for AD-relevant ChE molecular forms, brain vs. peripheral selectivity, and pharmacokinetic profile may be important determinants of the acute and long-term efficacy, safety and tolerability profiles of the different ChE-Is. This review focuses on new evidence for the roles of BuChE and AChE in symptom generation and rate of underlying disease progression in dementia, and argues that it may be appropriate to re-evaluate the place of ChE-Is in the treatment of dementia.
Lane
Roger M
RM
Novartis Neuroscience, Novartis Pharmaceuticals Corporation, NJ, USA.
Potkin
Steven G
SG
Enz
Albert
A
D000110:Acetylcholinesterase / Q000235:genetics / Q000378:metabolism; D000544:Alzheimer Disease / Q000188:drug therapy / Q000201:enzymology / Q000503:physiopathology; D000818:Animals; D002091:Butyrylcholinesterase / Q000235:genetics / Q000378:metabolism*; D002490:Central Nervous System / Q000201:enzymology; D002560:Cerebrovascular Circulation / Q000187:drug effects; D002799:Cholinergic Fibers / Q000473:pathology; D002800:Cholinesterase Inhibitors / Q000493:pharmacokinetics / Q000494:pharmacology*; D003704:Dementia / Q000188:drug therapy / Q000201:enzymology* / Q000503:physiopathology; D016503:Drug Delivery Systems; D005786:Gene Expression Regulation; D006801:Humans; D007527:Isoenzymes; D009457:Neuroglia / Q000201:enzymology; D011110:Polymorphism, Genetic
D002800:Cholinesterase Inhibitors; D007527:Isoenzymes; D000110:Acetylcholinesterase; D002091:Butyrylcholinesterase